Solid dosage form comprising a fibrate

Details Solid dosage form comprising a fibrate Solid dosage form comprising a fibrate

2004-10-01

2010-02-09

Wax, Robert A (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

Reexamination Certificate

active

07658944

ABSTRACT:
The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.

REFERENCES:
patent: 4603143 (1986-07-01), Schmidt et al.
patent: 4629624 (1986-12-01), Grouiller et al.
patent: 4719228 (1988-01-01), Rawlins et al.
patent: 4800079 (1989-01-01), Boyer et al.
patent: 4816264 (1989-03-01), Phillips et al.
patent: 5082655 (1992-01-01), Snipes et al.
patent: 6027747 (2000-02-01), Terracol et al.
patent: 6039981 (2000-03-01), Woo et al.
patent: 6096337 (2000-08-01), Spireas et al.
patent: 6287587 (2001-09-01), Shigeyuki et al.
patent: 6350398 (2002-02-01), Breitenbach et al.
patent: 6372251 (2002-04-01), Liu et al.
patent: 6569463 (2003-05-01), Patel et al.
patent: 7022337 (2006-04-01), Liang et al.
patent: 7217431 (2007-05-01), Holm et al.
patent: 7255877 (2007-08-01), Parikh
patent: 2002/0056206 (2002-05-01), Pace et al.
patent: 2002/0058065 (2002-05-01), Guivarc'h et al.
patent: 2002/0161032 (2002-10-01), Guivarc'h et al.
patent: 2003/0077297 (2003-04-01), Chen et al.
patent: 2003/0082215 (2003-05-01), Lemut et al.
patent: 2003/0162827 (2003-08-01), Venkataram et al.
patent: 2003/0180352 (2003-09-01), Patel et al.
patent: 2003/0180367 (2003-09-01), Parikh et al.
patent: 2004/0058005 (2004-03-01), Stamm et al.
patent: 2006/0222706 (2006-10-01), Flashner-Barak et al.
patent: 2006/0222707 (2006-10-01), Lerner et al.
patent: 2007/0015834 (2007-01-01), Flashner-Barak et al.
patent: 2007/0148233 (2007-06-01), Lerner et al.
patent: 2253769 (2000-09-01), None
patent: 2621873 (1977-11-01), None
patent: 2631873 (1977-11-01), None
patent: 2001 011249 (2001-02-01), None
patent: WO 95/06460 (1995-03-01), None
patent: WO 95/06460 (1995-03-01), None
patent: WO9506460 (1995-03-01), None
patent: WO 01/34119 (1999-11-01), None
patent: WO-00/45817 (2000-08-01), None
patent: WO-00/50007 (2000-08-01), None
patent: WO 00/57918 (2000-10-01), None
patent: WO 03/004001 (2001-07-01), None
patent: WO01/95939 (2001-12-01), None
patent: WO 0195939 (2001-12-01), None
patent: WO 03/013608 (2003-02-01), None
patent: 03/103640 (2003-12-01), None
patent: WO-2004041250 (2004-05-01), None
patent: WO-2004/073686 (2004-09-01), None
patent: WO-2004/073689 (2004-09-01), None
Sheu et al., Int. J. Pharm. Int. J. Pharmaceutics, vol. 102, No. 2, pp. 137-146.
Athyros et al. “Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes with Combined Hyperlipidemia, Diabetes Care” 25: 1198-1202, 2002, printed pp. 1-13, especially p. 2, Research Design and Methods.
Lee, J. “Research Article: Drug nano- and microparticles processed into solid dosage forms: Physical Properties”, Journal of Pharmaceutical Science, vol. 92, Issue 10, pp. 2057-2068, Published online: Jul. 30, 2003.
Office Action for U.S. Appl. No. 11/449,918 mailed Jan. 30, 2009; 23 pages.
Vasilios et al.: “Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes with Combined Hyperlipidemia” Diabetes Care. 25:1198-1202. 2002.
Center for Drug Evaluation and Research. Apr. 11, 2000. Application No. 19-304/5005. Tricor® (fenofibrate capsules). Final Printed Labeling.
Davidson, Michael H et al. “Abstract 5069: Atorvastatin/Fenotibrate 40/100 mg Fixed-Dose Combination tablet (LCP-AtorFen 40/100 mg) Offers Improved Efficacy Over 40 mg Atorvastatin and Higher Dose 145 mg Fenotibrate in Patients with Dyslipidemia” Circulation 2008; 118:8-1139.

Affiliated with

Also associated with

Rating

Solid dosage form comprising a fibrate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Solid dosage form comprising a fibrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid dosage form comprising a fibrate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4219474